HJY28 (ranibizumab biosimilar) / Huadong Medicine - LARVOL DELTA

Huadong Medicine: Application for marketing authorization of ranibizumab injection accepted [Google translation] (Sina Corp) - "CSI Smart Finance Huadong Medicine...announced on June 3 that the marketing authorization application for ranibizumab injection (R&D code HJY28) submitted by the company's wholly-owned subsidiary Hangzhou Sino-US Huadong Pharmaceutical Co., Ltd. has been accepted. Ranibizumab injection is indicated in adults for the treatment of wet (neovascular) age-related macular degeneration (AMD), the treatment of visual impairment caused by diabetic macular edema (DME), the treatment of diabetic retinopathy (DR) [proliferative diabetic retinopathy (PDR) and moderate to severe non-proliferative diabetic retinopathy (NPDR)], the treatment of visual impairment caused by macular edema secondary to retinal vein occlusion (RVO) (branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)), and the treatment of visual impairment caused by choroidal neovascularization (CNV, i.e. CNV secondary to pathological myopia (PM) and other causes)."

China filing • Age-related Macular Degeneration • Diabetic Macular Edema • Diabetic Retinopathy